Literature DB >> 33408286

Consensus Guidelines on Management of Steroid-Resistant Nephrotic Syndrome.

Anil Vasudevan1, Ranjeet Thergaonkar2, Mukta Mantan3, Jyoti Sharma4, Priyanka Khandelwal5, Pankaj Hari5, Aditi Sinha5, Arvind Bagga6.   

Abstract

JUSTIFICATION: The management of steroid resistant nephrotic syndrome (SRNS) is challenging. These guidelines update existing 2009 Indian Society of Pediatric Nephrology recommendations on its management.
OBJECTIVE: To frame revised guidelines on diagnosis and evaluation, treatment and follow up, and supportive care of patients with the illness. PROCESS: The guidelines combine evidence-based recommendations and expert opinion. Formulation of key questions was followed by systematic review of literature, evaluation of evidence by experts and two face-to-face meetings. RECOMMENDATIONS: Fourteen statements provide updated advice for managing steroid resistance, and underscore the importance of estimating proteinuria and baseline kidney function, and the need for kidney biopsy and genetic screening. Calcineurin inhibitors are recommended as most effective in inducing remission of proteinuria, the chief factor associated with long-term renal survival. Advice on managing allograft recurrence, congenital nephrotic syndrome, and monitoring and supportive care, including transition of care, are described. This revised practice guideline is intended to improve management and patient outcomes, and provide direction for future research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33408286

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  2 in total

1.  Genetic studies of nephrotic syndrome in Egyptian children.

Authors:  Rehab Elmougy
Journal:  J Appl Biomed       Date:  2021-10-12       Impact factor: 1.797

2.  Institute of Child Health, Kolkata, 1956-2022.

Authors:  Apurba Ghosh; Surupa Basu; Ritabrata Kundu
Journal:  Indian Pediatr       Date:  2022-09-15       Impact factor: 3.839

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.